MedPath

Promus - Registry Experience at the Washington Hospital Center, Drug-eluting Stent (DES)

Withdrawn
Conditions
Coronary Artery Disease
Registration Number
NCT01003795
Lead Sponsor
Medstar Health Research Institute
Brief Summary

Single-center registry of patients treated with at least one Promus, everolimus-eluting, Stent, with the primary objective to assess clinical success and safety at 30 days, 6 months and 1 year post-implantation.

Detailed Description

Interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (BMS) and recently with the drug-eluting stents (DES). The everolimus eluting stents have shown very promising results in randomized clinical trials, demonstrating a reduction of clinical and angiographic restenosis in comparison to BMS, and comparable clinically-driven target lesion revascularization rates in comparison with sirolimus-eluting stents. While registry data is available from outside of the United States, it will be important to collect "real-world" data regarding the stent usage and outcomes in the United States. In this study we propose to follow patients who received at least one Promus® Stent for at least 1 year post initial stent implantation.

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients, male or female, >18 years of age
  • Patients who received at least one Promus drug-eluting stent at the Washington Hospital Center
Exclusion Criteria
  • N/A

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluation of Major Adverse Cardiac Events (MACE) post Promus Stent implantationFollow up
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Washington Hospital Center

🇺🇸

Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath